SUMMARY
INTRODUCTION
Histone modifications are believed to modulate chromatin function in transcription regulation by altering its structure and establishing an epigenetic signature, the proposed histone code (1) . In recent years, numerous studies have identified enzymes responsible for acetylation, phosphorylation and methylation of histone N-terminal tails. While these enzymes are often part of multisubunit complexes directly involved in the control of gene expression, they target very specific residues which, in turn, can modulate the subsequent action of other histone modifying enzymes (2) . The specific modified residues can themsleves be recognized by protein modules present in many transcription regulators and could translate the histone code, e.g.
bromodomains for acetyl-lysines and chromodomains for methyl-lysines (1).
In Saccharomyces cerevisiae, a number of genes contain a SET domain, a putative histone methyltransferase (HMT) domain. Indeed, Set1 has been shown to methylate histone H3 lysine-4 in vivo, a reaction important for gene silencing (3). Set2 was recently characterized and shown to methylate nucleosomal histone H3 on lysine-36 (4). The specific activity of Set2 on chromatin substrates but not free histones is a striking new characteristic for an HMT.
Arginine residues on histone tails are also known to be targeted for methylation.
For example, human PRMT1 is responsible for in vivo dimethylation of histone H4 on arginine-3 which in turn can modulate subsequent H4 acetylation by p300 in vitro and coactivates nuclear receptor-driven transcription (5) . The major arginine methyltransferase in Saccharomyces cerevisiae is the closely related Rmt1 (arginine methyltransferase-1) (6) . Rmt1 has been shown to act as a hnRNP methyltransferase in vivo (7) . Homology searches with known S-adenosyl methionine (AdoMet) methyltransferase domains also identified Dot1 (Disruptor of telomeric silencing-1) as a putative protein methyltransferase (8) . The Dot1 AdoMet-binding domain is also related to the one present in Rmt1. Dot1 is important for telomere silencing as well as for the pachytene checkpoint during meiotic cell cycle (9, 10) . Deletion of DOT1 results in mislocalization of silencing regulators Sir2 and Sir3 (10) .
In this paper, we characterize two novel histone methyltransferases from yeast Saccharomyces cerevisiae. Using purified yeast chromatin, we show that the transcription silencing regulator Dot1 contains intrinsic HMT activity that targets the globular domain of nucleosomal histone H3. In contrast, Rmt1 can only act on free histones and methylates arginine-3 on the H4 N-terminal tail. 
EXPERIMENTAL PROCEDURES

Strains and recombinant proteins
The S. cerevisiae strains BY4741, ∆dot1 and ∆rmt1 were obtained from Research Genetics. The strain expressing Rmt1-TAP was obtained from Euroscarf. The protocol used to insert the TAP (tandem-affinity purification) cassette at the C-terminus of Dot1 in the endogenous gene is described by Puig et al. (11) . Plasmid pBS1479 was used to amplify the TAP cassette for transformation. TAP-fusion with endogenous Dot1 protein was confirmed by western blot (not shown). His-tagged recombinant Dot1 was produced by cloning in pET15b (Novagen) a PCR fragment containing the ORF using NdeI and BamHI sites. His-tagged recombinant Esa1 and GST-Rmt1 have been described (6, 12) . Each recombinant protein was purified using standard procedures.
Purification of free core histones and native chromatin
Purification of human core histones and oligonucleosomes was performed as described (13) . Acid-extracted core histones from yeast cells were obtained as described (14) . Yeast native chromatin purification was performed with modifications of the protocol used for mammalian cells (13) using yeast nuclei prepared as described (14) and adding 2 µg/ml leupeptin, 2 µg/ml pepstatin, 5 µg/ml aprotinin, 5 mM sodium butyrate, 5 mM β glycerophosphate 0.5 mM spermidine, 0.15 mM spermine to all buffers. After concentration, the sample (2 ml) was fractionated by gel filtration (superose 6, Pharmacia). Fractions (0.5 ml) containing dinucleosomes and longer chromatin fragments (>300 base pairs) were pooled, concentrated and stored at ˘80 o C. TAP system purification was performed as described by Puig et al (11) using 250 ml of yeast culture (OD 600 ~2.5). 10 % glycerol, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM DTT, 2 µg/ml leupeptin and pepstatin, 5 µg/ml aprotinin were added to the extraction buffer. The extract was precleared with 50 µl of sepharose CL-6B before binding to 50 µl of IgG sepharose (Pharmacia). Elution with 10 U of TEV protease (Gibco) was done in 100 µl. 50 µl of calmodulin beads (Stratagene) were used for subsequent binding overnight at 4°C. Elution was performed overnight with 50µl of elution buffer containing 10 mM EGTA.
Purification of Dot1 and Rmt1 from yeast
Histone methyltransferase assays and western blots
HMT assays were performed in 20 µl using 0.5 µg of core histones or oligonucleosomes and were typically used for western blotting after electrophoresis on a 18% SDS-PAGE.
Immunoblotting was performed according to the manufacturer's instructions for specific antibodies. Anti-dimethyl K36-H3, R17-H3, R27-H3, K4-H3 and R3-H4 and anti-Acetyl H4 (also specific for acetylated H2A in yeast) and H3 were purchased from Upstate Biotechnology. Anti-Acetyl K5-H4, K8-H4, K12-H4 and K16-H4 were from Serotec. 
V8 protease digestion and mass spectrometry analysis
For the histone peptide mapping experiment, 2 µg of histones or oligonucleosomes were methylated or acetylated in vitro and samples were then precipitated with TCA, resuspended in 20 µl of 25 mM NH 4 HCO 3 pH 7.8, SDS 0.1%. 0.5 µg of histones were digested with one unit of V8 endoprotease (Sigma) for 18h at 25 o C. Samples were then loaded on a 16.5% SDS-PAGE in Tris-tricine buffer. Purification of native histone acetyltransferase (HAT) complexes used as controls and HAT assay conditions have been described (12) . For MALDI-TOF analysis, 10 µg of oligonucleosomes radioactively methylated by Dot1 were loaded on a 18% SDS-PAGE. After staining, the histone H3 band was cut and digested with V8 protease. The peptides produced were separated on a C18 reverse phase HPLC column and mass spectra for the fraction containing radioactivity was acquired on a MALDI-TOF mass spectrometer (Applied Biosystems).
Spectra were acquired in positive ion mode and calibrated using an external calibration sample.
RESULTS AND DISCUSSION
Dot1 methylates nucleosomal histone H3 but not free histones while Rmt1 only methylates free histone H4
Initially searching for histone methyltransferases that could modulate subsequent acetylation of histone H4 tail by histone acetyltransferases (HATs) in Saccharomyces cerevisiae, we produced recombinant proteins corresponding to two putative yeast HMTs, Rmt1 and Dot1. Rmt1 is homologous to human PRMT1 which was recently shown to methylate histone H4 N-terminal tail (5). Chromatin silencing protein and meiotic recombination checkpoint regulator Dot1 contains a putative AdoMet methyltransferase domain related to the one present in Rmt1 (8) (9) (10) . These recombinant proteins were tested for histone methyltransferase activity against human free core histones and H1-depleted oligonucleosomes in the presence of 3 H-AdoMet. As shown in figure 1A, Rmt1 clearly methylates free histone H4 in these conditions, and histone H2A to a lesser extent while the GST control has no activity (lanes [7] [8] . This demonstrates that Rmt1 has an intrinsic HMT activity which is similar to that reported for human PRMT1 (5). However Rmt1 does not methylate histones in the context of chromatin (lanes 3-4). In the case of Dot1, no activity was detected when free histones were used as substrate (lanes 5-6). In contrast, efficient methylation of histone H3 was detected when oligonucleosomes were used as substrate, while the control Esa1 acetyltransferase showed no activity (lanes 1-2). This demonstrates that, as for Rmt1, Dot1 also has intrinsic HMT activity but with strikingly different specificity as it modifies histone H3 only in the context of chromatin. This activity is likely functionally linked to Dot1 role in chromatin silencing.
In an effort to confirm the HMT activities detected within the bacteriallyexpressed recombinant proteins, we purified endogenous yeast Dot1 and Rmt1 using the TAP system (11). This system allows purification of physiological levels of proteins since the TAP-tag is inserted at the end of the chromosomal gene, retaining should be present in these conditions which could potentially modify each HMT activity and specificity as it has been shown before for HATs. Purified material is shown in figure 1B along with a control non-tagged strain (to distinguish non-specific bands).
Rmt1 was obtained in sufficient amount and no clear stochiometric associated protein was detected (lane 2). Though a lesser quantity of Dot1 was obtained, two or three potential associated proteins were detected (compare lane 1 and 3). We then used these fractions in HMT assays as shown in figure 1A . Surprisingly, purified yeast Rmt1 did not demonstrate any HMT activity on either free histones or chromatin substrates (Fig.   1C, lanes 2 and 5) . Conclusions about this result are complicated by the fact that Rmt1 was shown to oligomerize as a hexamer (15) . The presence of the large TAP-tag (protein A plus calmodulin-binding peptide) at the C-terminus of Rmt1 could potentially block natural oligomerization, creating a catalytically inactive protein. In the case of Dot1, HMT activity was detected in the purified fraction identical to that which was obtained with the bacterially-expressed protein (Fig. 1C, lanes 1 and 4) . Thus, we conclude that Dot1 has genuine chromatin-specific histone H3 methyltransferase activity.
To further support the relevance of the activities we detect in our in vitro HMT assays, we purified the natural substrate for Dot1 and Rmt1, i.e. core histones and chromatin from Saccharomyces cerevisiae. While purification of free core histones by acid extraction is reliable for yeast nuclei, purification of yeast native chromatin has been historically considered a challenging task. We adapted the protocol used for mammalian cells (see experimental procedures) and obtained good quality purified figure 1A and similar results were obtained ( Fig. 2A, lanes 1 and 7) . On the other hand, yeast histone H2A was not methylated by Rmt1, which could reflect the lower sequence conservation of this specific histone tail. Interestingly, Dot1 methylated tH3 as efficiently as full-length H3, suggesting that residue(s) modified by Dot1 are located downstream of serine-22. The same experiment was repeated using purified yeast Dot1 and Rmt1. Unfortunately, Rmt1 was also inactive on yeast histones (Fig. 2B , lane 5). Purified Dot1 behaved exactly like the bacterially expressed protein, methylating nucleosomal histone H3 and tH3 while inactive on free yeast histones (lanes 3 and 6).
Dot1 specifically methylates the globular domain of nucleosomal H3 while Rmt1 dimethylates arginine-3 of histone H4 N-termini
Specifically mapping the residues modified by new histone modifying activities is an important means to understanding the histone code and the role of these enzymes in chromatin structure and function. In an attempt to do so we performed HMT assays in presence of non-radioactive AdoMet to subsequently analyze Dot1-and Rmt1-modified histones by western blot using available antibodies against specific known modified residues on histone tails (Fig. 3A) . Since both Dot1 and Set2 are chromatinspecific H3 methyltransferases, we first looked at the Set2 target on H3 tail, i.e. lysine-36 (4). While dimethyl-lysine-36 signal was detected in all the histone and chromatin samples, yeast or human, no variation was observed in the presence of Dot1 (lanes 1-4) . We then tested if loss of Dot1 or Rmt1 in vivo would affect the abundance of certain modified histone isoforms. Yeast core histones were purified from ∆dot1, ∆rmt1
and wild type strains and were analyzed with antibodies against specific histone modifications (Fig. 3B) . As in the in vitro assay, Dot1 had no significant effect on the levels of H3 MeK36 (lane 1 versus 3, the slight difference in signal corresponds to the amount of histones loaded). This is in agreement with the fact that Set2 is likely the signal is detected in yeast core histones after long exposure (Fig. 3B, lanes 1-3, lower   panel) . While H4-R3 is the clear substrate of Rmt1 in in vitro HMT assays, loss of Rmt1 protein in vivo does not have a significant effect on the weak western signal (lane 2 versus 3). This argues that Rmt1 might not be the sole H4-R3 HMT in yeast and that its action could be very localized. We also tested other available antibodies, including Set1 target, H3-MeK4 (3) and histone H3, H2A and H4 acetylated isoforms (lanes 4-6).
While loss of Dot1 does not change the level of MeK4-H3 in the cell, it provokes a significant increase of bulk histone acetylation. AcK5-H4 shows the strongest increase followed by AcH2A, AcK8-H4, Ac-K12-H4 and AcH3 (compare lanes 5 and 6). HMT reaction. Since methylation occurs downstream of serine-21, we sequenced tH3 (see figure 2) . Surprisingly, no 3 H-labeled residues were detected during 23 cycles of Edman degradation, indicating that Dot1 does not methylate the N-terminal domain of histone H3 (H3 globular domain begins at amino acid 45 (16)). This suggests a new concept of histone methyltransferase targeting the globular domain of a specific histone in chromatin. We confirmed this hypothesis by using an endoprotease to map the peptide region(s) within H3 that are labeled by Dot1 (Fig. 3C) residue is an unlikely target as its side-chain is buried in the nucleosomal DNA minor groove (16) . In contrast, lysine-79 is accessible at the surface of the nucleosome and has even been reported to be methylated in vivo in C. elegans (19) , an organism that contains homologs of Dot1 (10) . Furthermore, while this work was under review, two independent studies reported similar findings, linking Dot1 to methylation of histone H3 lysine-79 (20, 21) . Our data also demonstrate that Dot1 trimethylates lysine-79 in nucleosomal histone H3.
In this report we have characterized a new histone methyltransferase which 
